Upstream Bio Advances Phase 3 Trials for Verekitug in Severe Asthma and CRSwNP — Upstream Bio, Inc.

Event summary

Upstream Bio completed enrollment in the Phase 2 VENTURE trial for COPD with 481 participants, data expected in H2 2027.
Phase 3 trials for severe asthma and CRSwNP are on track to initiate in Q1 2027, with End-of-Phase 2 FDA interactions progressing as planned.
Verekitug demonstrated statistically significant improvements in CRSwNP and comorbid asthma symptoms at ATS and EAACI congresses.
Upstream Bio reported $261.3 million in cash reserves as of June 30, 2026, sufficient to fund operations through 2027.

The big picture

Upstream Bio is advancing its lead candidate, verekitug, through late-stage clinical development for severe inflammatory respiratory diseases. The company’s focus on TSLP receptor inhibition positions it in a growing market of targeted therapies for asthma and CRSwNP, where convenient dosing regimens could drive adoption. Success hinges on regulatory alignment and robust Phase 3 data to differentiate from existing treatments.

What we're watching

Regulatory Approval: The outcome of End-of-Phase 2 FDA interactions will determine the design and timeline for Phase 3 trials in severe asthma and CRSwNP.
Clinical Data Impact: Upcoming data from the VENTURE trial in COPD and VALOUR LTE study in severe asthma could further validate verekitug’s differentiated profile.
Market Differentiation: The pace at which Upstream Bio can establish verekitug as a best-in-class treatment with quarterly dosing will be critical for competitive positioning.